Oracle: Q1 FY2027 Capex ($28.5B) Exceeded Operating Cash Flow ($23.1B) — and the Stock Has Now Lost 54% From Its High
Update to the Q1 FY2027 story (capex surge funded by the $20B ATM — see prior revision): the market view as of Oct 12 confirms the quarter's funding math — quarterly capex $28.50B vs operating cash flow $23.10B (FCF -$5.40B), total debt $155.93B (4.5x EBITDA), cash $36.37B. The operating story still beats: TTM revenue +29.6% ($71.78B), EPS $1.63 vs $1.39 est (+17% beat), fourth consecutive beat. But the equity has re-rated brutally: $141.40, -54.2% below its 52-week high, -11.9% below its 200-day moving average (ORCL market view, 2026-10-12) — against NVDA at -4.2% and TSM -6.7% off their highs. The stock fell 5.5% on Oct 8 in the OpenAI revenue-gap selloff (Oracle's backlog is the most OpenAI-levered in the chain) and rebounded +4.6% on Oct 9 (TheStreet).
Context from this cycle's reporting: Broadcom and Oracle are together seeking $50B in financing for OpenAI (Reuters via TheStreet); Oracle guides FY2027 capex of $90–95B; and S&P cut Oracle to BBB- in July 2026 as the AI buildout widened its cash deficit to $42B (PPC Land).
What it means
Oracle is now the clearest expression of the funding-layer divergence (Hyperscaler Capex: Five-Way 2026 Total Now ~$800B; Cloud Revenue Growth Is the Counterweight to Funding-Layer Stress): hyperscale growth bought with the balance sheet rather than cash flow. With the 10-year Treasury at 5.22% and the Fed signaling one more hike (Oct 28 FOMC), the equity is pricing real probability that either OpenAI-linked backlog converts slower than contracted (OpenAI's Revenue Run-Rate Gap: ~$50B vs the ~$70B Circulated — and What It Did to the Capex Chain) or refinancing costs compress the spread between RPO growth and interest expense. Watch the December Q2 FY2027 print for capex vs OCF trajectory, any ATM follow-on, and credit-spread direction.